These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 36620614)

  • 1. Aprocitentan: New insights.
    Varzideh F; Kansakar U; Jankauskas SS; Santulli G
    Front Cardiovasc Med; 2022; 9():1093406. PubMed ID: 36620614
    [No Abstract]   [Full Text] [Related]  

  • 2. Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant Hypertension.
    Angeli F; Verdecchia P; Reboldi G
    Cardiol Ther; 2021 Dec; 10(2):397-406. PubMed ID: 34251649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying and treating resistant hypertension in PRECISION: A randomized long-term clinical trial with aprocitentan.
    Danaietash P; Verweij P; Wang JG; Dresser G; Kantola I; Lawrence MK; Narkiewicz K; Schlaich M; Bellet M;
    J Clin Hypertens (Greenwich); 2022 Jul; 24(7):804-813. PubMed ID: 35686330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension.
    Verweij P; Danaietash P; Flamion B; Ménard J; Bellet M
    Hypertension; 2020 Apr; 75(4):956-965. PubMed ID: 32063059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension: A Systematic Review and Meta-Analysis.
    Mahfooz K; Najeed S; Tun HN; Khamosh M; Grewal D; Hussain A; Ong K; Dharmarajan L; Vasavada A
    Curr Probl Cardiol; 2023 Jul; 48(7):101686. PubMed ID: 36893968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological Characterization of Aprocitentan, a Dual Endothelin Receptor Antagonist, Alone and in Combination with Blockers of the Renin Angiotensin System, in Two Models of Experimental Hypertension.
    Trensz F; Bortolamiol C; Kramberg M; Wanner D; Hadana H; Rey M; Strasser DS; Delahaye S; Hess P; Vezzali E; Mentzel U; Ménard J; Clozel M; Iglarz M
    J Pharmacol Exp Ther; 2019 Mar; 368(3):462-473. PubMed ID: 30622171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absorption, Distribution, Metabolism, and Excretion of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Humans.
    Sidharta PN; Fischer H; Dingemanse J
    Curr Drug Metab; 2021; 22(5):399-410. PubMed ID: 33563190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aprocitentan and the endothelin system in resistant hypertension.
    Clozel M
    Can J Physiol Pharmacol; 2022 Jul; 100(7):573-583. PubMed ID: 35245103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment.
    Fontes MSC; Dingemanse J; Halabi A; Tomaszewska-Kiecana M; Sidharta PN
    Sci Rep; 2022 Nov; 12(1):19067. PubMed ID: 36352054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Multiple-Dose Administration of Aprocitentan on the Pharmacokinetics of Rosuvastatin.
    Sidharta PN; Dingemanse J
    Clin Pharmacol Drug Dev; 2020 Nov; 9(8):995-1002. PubMed ID: 32592633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple-Dose Pharmacokinetics, Safety, and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Healthy Japanese and Caucasian Subjects.
    Fontes MSC; Dingemanse J; Sidharta PN
    Clin Pharmacol Drug Dev; 2021 Jul; 10(7):718-725. PubMed ID: 33063477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects.
    Sidharta PN; Melchior M; Kankam MK; Dingemanse J
    Drug Des Devel Ther; 2019; 13():949-964. PubMed ID: 30962677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-Dose Pharmacokinetics and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Subjects with Severe Renal Function Impairment.
    Sidharta PN; Ulč I; Dingemanse J
    Clin Drug Investig; 2019 Nov; 39(11):1117-1123. PubMed ID: 31435905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Population Pharmacokinetic Model of Macitentan and Its Active Metabolite Aprocitentan in Healthy Volunteers and Patients with Pulmonary Arterial Hypertension.
    Bartolucci R; Dosne AG; Csonka D; Pérez-Ruixo JJ; Magni P; Poggesi I
    Clin Pharmacokinet; 2021 Dec; 60(12):1605-1619. PubMed ID: 34159557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Multiple-Dose Aprocitentan Administration on the Pharmacokinetics of Midazolam in Healthy Male Subjects.
    Sidharta PN; Dingemanse J
    Eur J Drug Metab Pharmacokinet; 2020 Apr; 45(2):227-234. PubMed ID: 31773427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aprocitentan (a Dual Endothelin-Receptor Antagonist) for Treatment-Resistant Hypertension.
    McCoy EK; Lisenby KM
    J Cardiovasc Pharmacol; 2021 Jun; 77(6):699-706. PubMed ID: 34001723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the Dual Endothelin Receptor Antagonist Aprocitentan on Body Weight and Fluid Homeostasis in Healthy Subjects on a High Sodium Diet.
    Gueneau de Mussy P; Sidharta PN; Wuerzner G; Maillard MP; Guérard N; Iglarz M; Flamion B; Dingemanse J; Burnier M
    Clin Pharmacol Ther; 2021 Mar; 109(3):746-753. PubMed ID: 32897570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on Endothelin Receptor Antagonists in Hypertension.
    Burnier M
    Curr Hypertens Rep; 2018 May; 20(6):51. PubMed ID: 29779164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New and developing pharmacotherapies for hypertension.
    Höcht C; Allo MA; Polizio AH; Morettón MA; Carranza A; Chiappetta DA; Choi MR
    Expert Rev Cardiovasc Ther; 2022 Aug; 20(8):647-666. PubMed ID: 35880547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endothelin, hypertension and chronic kidney disease: new insights.
    Kohan DE
    Curr Opin Nephrol Hypertens; 2010 Mar; 19(2):134-9. PubMed ID: 20051851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.